Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

BackgroundThe prognostic value of androgen receptor splice variant 7 (AR-V7) for the treatment response of metastatic castration-resistant prostate cancer (mCRPC) remains unclear. In this study, we aimed to synthesize relevant studies that assessed the prognostic value of AR-V7 status for the treatm...

Full description

Bibliographic Details
Main Authors:	Jiaxin Wang, Yucong Zhang, Chao Wei, Xintao Gao, Penghui Yuan, Jiahua Gan, Rui Li, Zhuo Liu, Tao Wang, Shaogang Wang, Jihong Liu, Xiaming Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-11-01
Series:	Frontiers in Oncology
Subjects:	androgen receptor splice variant 7 metastatic castration-resistant prostate cancer prognosis androgen receptor signaling inhibitors chemotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2020.562504/full

Similar Items

Data of relative mRNA and protein abundances of androgen receptor splice variants in castration-resistant prostate cancer
by: Tianfang Ma, et al.
Published: (2021-02-01)

Regulation of androgen receptor variants in prostate cancer
by: Yezi Zhu, et al.
Published: (2020-07-01)

Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer
by: Mercedes Marín-Aguilera, et al.
Published: (2020-01-01)

Mechanisms behind growth of castration-resistant prostate cancer bone metastases
by: Jernberg, Emma
Published: (2013)

LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models
by: Sergio Regufe da Mota, et al.
Published: (2018-05-01)

Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy
by: Yasuomi Shimizu, et al.
Published: (2018-11-01)

Clinicopathological characteristics of androgen receptor splicing variant 7 (AR-V7) expression in patients with castration resistant prostate cancer: A systematic review and meta‐analysis
by: Qinchen Li, et al.
Published: (2021-09-01)

AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel
by: Anieta M. Sieuwerts, et al.
Published: (2019-08-01)

Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective
by: Jo-Lynn Tan, et al.
Published: (2017-12-01)

Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer
by: Jun Luo
Published: (2016-01-01)

Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy
by: Vincent Wing Sun Liu, et al.
Published: (2017-05-01)

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
by: Alexandra Vander Ark, et al.
Published: (2018-05-01)

Registered report: androgen receptor splice variants determine taxane sensitivity in prostate cancer
by: Xiaochuan Shan, et al.
Published: (2015-09-01)

Replication study: androgen receptor splice variants determine taxane sensitivity in prostate cancer
by: Xiaochuan Shan, et al.
Published: (2018-04-01)

Abiraterone Rechallenge Based on Sequential Testing of Androgen Receptor Splice Variant 7 Expression in Circulating Tumor Cells: A Case Report
by: Naoya Nagaya, et al.
Published: (2020-04-01)

AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption
by: Navid Sobhani, et al.
Published: (2021-05-01)

Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer
by: Steven K. Nordeen, et al.
Published: (2021-08-01)

A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
by: Crowley F, et al.
Published: (2021-06-01)

Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer
by: Osamu Ogawa, et al.
Published: (2013-07-01)

Molecular Phenotyping of AR Signaling for Predicting Targeted Therapy in Castration Resistant Prostate Cancer
by: Agus Rizal A. H. Hamid, et al.
Published: (2021-08-01)

AR Splicing Variants and Resistance to AR Targeting Agents
by: Mayuko Kanayama, et al.
Published: (2021-05-01)

The Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer Treated With Novel Hormonal Therapy or Chemotherapy: A Systematic Review and Meta-analysis
by: Zhize Wang, et al.
Published: (2020-11-01)

Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer
by: Doo Yong Chung, et al.
Published: (2021-06-01)

The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on Therapy
by: Elisabeth A. Messner, et al.
Published: (2020-10-01)

Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer
by: Paul S. Rennie, et al.
Published: (2013-06-01)

Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges
by: Yuki Kita, et al.
Published: (2018-09-01)

Androgen receptor and prostate cancer
by: Karen E. Livermore, et al.
Published: (2016-06-01)

Blocking GRP/GRP-R signaling decreases expression of androgen receptor splice variants and inhibits tumor growth in castration-resistant prostate cancer
by: Thomas C. Case, et al.
Published: (2021-11-01)

Effects of Sorafenib on <em>C</em>-Terminally Truncated Androgen Receptor Variants in Human Prostate Cancer Cells
by: Mark Schrader, et al.
Published: (2012-09-01)

Clinical relevance of androgen receptor alterations in prostate cancer
by: Emma Jernberg, et al.
Published: (2017-10-01)

How do we define “castration” in men on androgen deprivation therapy?
by: Sarin Itty, et al.
Published: (2020-01-01)

Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer
by: Fuqiang Ban, et al.
Published: (2021-07-01)

Differential Expression of the Androgen Receptor, Splice Variants and Relaxin 2 in Renal Cancer
by: Joanna Bialek, et al.
Published: (2021-07-01)

Current opportunities of therapy for patients with non-metastatic castration-resistant prostate cancer
by: B. Ya. Alekseev, et al.
Published: (2020-11-01)

Testosterone Deficiency Caused by Castration Modulates Mitochondrial Biogenesis Through the AR/PGC1α/TFAM Pathway
by: Can Liu, et al.
Published: (2019-05-01)

The AhR Ligand, TCDD, Regulates Androgen Receptor Activity Differently in Androgen-Sensitive versus Castration-Resistant Human Prostate Cancer Cells
by: Maryam Ghotbaddini, et al.
Published: (2015-07-01)

Loss of an Androgen-Inactivating and Isoform-Specific HSD17B4 Splice Form Enables Emergence of Castration-Resistant Prostate Cancer
by: Hyun-Kyung Ko, et al.
Published: (2018-01-01)

Darolutamide For Castration-Resistant Prostate Cancer
by: Bastos DA, et al.
Published: (2019-10-01)

Androgen receptor signaling in prostate cancer development and progression
by: Peter E Lonergan, et al.
Published: (2011-01-01)

Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
by: Gul A, et al.
Published: (2019-08-01)

Cannot write session to /tmp/vufind_sessions/sess_o34j6uj269hd3mue7fctdsul8k